Profits at Johnson & Johnson, New Brunswick, N.J., climbed 19% in the third quarter ended Sept. 30 in large part because of broad-based growth in medical device sales and the ongoing strength of its pharmaceutical business, company officials said. Net earnings rose to $1.8 billion, or 60 cents per share, compared with $1.5 billion, or 49 cents per share, for the year-ago period. Overall worldwide sales grew 12.7% to $9.1 billion. Drug sales grew 16.3% to $4.3 billion, while the medical devices and diagnostics business posted a 13.3% increase in sales to $3.1 billion. -- by Cinda Becker
J&J's profits climbs 19% as drug, device sales grow
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.